Endo International PLC (NASDAQ:ENDP) Director Roger H. Kimmel sold 14,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 15th. The shares were sold at an average price of $17.38, for a total value of $243,320.00. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Endo International PLC (NASDAQ:ENDP) traded up 0.731% during mid-day trading on Thursday, reaching $17.225. The company had a trading volume of 4,755,415 shares. The stock’s 50-day moving average price is $19.20 and its 200 day moving average price is $18.77. Endo International PLC has a 52 week low of $12.56 and a 52 week high of $63.71. The firm has a market capitalization of $3839.06 billion, a PE ratio of 1.893 and a beta of 0.67.

Endo International PLC (NASDAQ:ENDP) last released its quarterly earnings data on Tuesday, November 8th. The company reported $1.01 EPS for the quarter, topping the consensus estimate of $0.81 by $0.20. The company had revenue of $894.30 million for the quarter, compared to the consensus estimate of $862.47 million. Endo International PLC had a positive return on equity of 15.95% and a negative net margin of 3.32%. Endo International PLC’s quarterly revenue was up 18.6% on a year-over-year basis. During the same period last year, the business posted $1.02 EPS. On average, equities research analysts predict that Endo International PLC will post $4.59 EPS for the current year.

Insider Buying and Selling by Quarter for Endo International PLC (NASDAQ:ENDP)

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. RS Investment Management Co. LLC increased its position in Endo International PLC by 0.4% in the second quarter. RS Investment Management Co. LLC now owns 1,374,185 shares of the company’s stock valued at $21,424,000 after buying an additional 6,132 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Endo International PLC by 0.9% in the first quarter. Geode Capital Management LLC now owns 1,759,167 shares of the company’s stock worth $49,422,000 after buying an additional 15,173 shares in the last quarter. Babson Capital Management LLC increased its position in shares of Endo International PLC by 225.1% in the first quarter. Babson Capital Management LLC now owns 73,800 shares of the company’s stock worth $2,077,000 after buying an additional 51,100 shares in the last quarter. Lombardia Capital Partners LLC bought a new position in shares of Endo International PLC during the second quarter worth about $2,211,000. Finally, Jensen Investment Management Inc. bought a new position in shares of Endo International PLC during the second quarter worth about $434,000. Institutional investors own 96.96% of the company’s stock.

ENDP has been the topic of several research analyst reports. Zacks Investment Research raised Endo International PLC from a “sell” rating to a “hold” rating in a research note on Wednesday, July 20th. JPMorgan Chase & Co. reissued an “overweight” rating and set a $40.00 target price on shares of Endo International PLC in a research note on Tuesday, July 26th. Vetr raised Endo International PLC from a “buy” rating to a “strong-buy” rating and set a $19.14 target price on the stock in a research note on Monday, August 1st. Morgan Stanley set a $15.00 target price on Endo International PLC and gave the company a “hold” rating in a research note on Friday, August 5th. Finally, BMO Capital Markets reissued a “hold” rating and set a $22.00 target price on shares of Endo International PLC in a research note on Tuesday, August 9th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Endo International PLC has a consensus rating of “Buy” and a consensus price target of $31.63.

About Endo International PLC

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

5 Day Chart for NASDAQ:ENDP

Receive News & Stock Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related stocks with our FREE daily email newsletter.